New-onset, posttransplant diabetes mellitus (PTDM) has a high incidence after kidney transplantation in patients medicated with tacrolimus, and may adversely affect the patient and graft survival. The pathophysiology of PTDM closely mimics that of type II diabetes mellitus (T2DM). One of possible genetic factors predisposing to PTDM might be polymorphism in calpain-10 gene (CAPN10), previously associated with increased risk of T2DM in general population. Therefore, the present study was aimed at evaluation of CAPN10 gene polymorphisms in PTDM in kidney transplant patients medicated with tacrolimus. A total of 214 nondiabetic kidney transplant patients medicated with tacrolimus (56 patients with PTDM and 158 patients without PTDM were genotyped for the presence of CAPN10 gene variants (SNP-43: rs3792267:G4A, SNP-19: rs3842570 ins/del and SNP-63: rs5030952:C4T) using PCR-based assays. Frequency of SNP-63 minor allele was slightly increased in PTDM patients (P ¼ 0.056), and an association of SNP-63 heterozygosity and the risk of PTDM (odds ratios (OR) ¼ 2.45, P ¼ 0.023) was observed. An increased odds for PTDM development in patients carrying 1-1-2 haplotype (rs3792267:G-rs3842570:ins-rs5030952:T) compared to noncarriers was also noted (OR ¼ 2.35, P ¼ 0.026). Patients' higher body mass index and SNP-63 minor T allele carrier status were identified as independent PTDM risk factors, confirmed by multivariate regression analysis. This is the first study of CAPN10 polymorphism in relation to PTDM risk. However, the application of SNP-63 (rs5030952:C4T) as a marker of PTDM should be verified by further independent studies.
Introduction
New-onset, posttransplant diabetes mellitus (PTDM) has a high incidence after kidney transplantation in patients medicated with tacrolimus, and may adversely affect the patient and graft survival. 1 Estimates based on use of hypoglycemic intervention suggest that PTDM occurs in approximately 15-20% of renal transplant patients, whereas using American Diabetes Association (ADA) criteria it was found that 13% of patients had PTDM by 3 months after transplant and 39% had abnormal glucose metabolism. The onset of PTDM is most pronounced in the first few months after transplant, and continue to present with PTDM at a steady rate after the first year posttransplant. 2 Although there are currently no clearly established risk factors for PTDM, a number of characteristics have been identified that appear to predispose patients to the development of PTDM, such as patient age of over 40 years, African-American and Hispanic populations, family history, patient body weight, hepatitis C virus and the immunosuppressive regimen with calcineurin inhibitors. 3, 4 The pathophysiology of PTDM closely mimics that of type II diabetes mellitus (T2DM) and as such PTDM should be considered at least as serious as onset of T2DM. Both diseases are characterized by a combination of insulin resistance and insulin hyposecretion, although insulin hyposecretion appears to be a key determinant of worsening glucose tolerance following renal transplantation. 5, 6 The ability to predict a patient's risk for PTDM would be of considerable benefit in selecting appropriate immunosuppressive regimens for individuals. Therefore, some research studies were designed to reveal association of genetic factors with PTDM. Many of them have failed to identify such associations (including polymorphisms in CYP3A5, MDR1, UPC2, PPARg genes). However, Numakura et al. 7 reported that the presence of the vitamin D receptor gene VDR TaqI t allele may be a risk factor for PTDM, suggesting that genotyping of diabetes-related polymorphisms is a possible method of predicting a patient's risk for developing PTDM and would be a valuable asset in selecting appropriate immunosuppressive regimens for individuals.
One of possible genetic factors predisposing to PTDM might be polymorphism in calpain-10 gene (CAPN10). The gene encodes a nonlysosomal cysteine protease that is expressed, among others, in pancreatic islets, liver, skeletal muscle and fat, which is important in the regulation of glucose homeostasis. 8, 9 There is some evidence that CAPN10 genetic variants may affect either CAPN10 gene expression or mRNA stability. 8, 10, 11 Significant associations of one single nucleotide polymorphism (SNP-43, rs3792267), and a 'high-risk' haplotype combination 1-1-2/1-2-1 inferred from SNP-43 (rs3792267), SNP-19 (rs3842570) and SNP-63 (rs5030952) (allele 1: SNP-43 G, SNP-19 del ¼ 2 repeats, SNP-63 C; allele 2: SNP-43 A, SNP-19 ins ¼ 3 repeats, SNP-63 T) with increased risk of T2DM in three independent populations. 8 Two meta-and pooled analyses in large groups of cases and controls (43500 each) have shown association of SNPs within CAPN10 gene with T2DM. 12, 13 Therefore, the present study was aimed at evaluation of CAPN10 gene polymorphisms in PTDM in kidney transplant patients medicated with tacrolimus.
Materials and methods

Patients
A total of 214 nondiabetic kidney transplant patients (patients with diabetes mellitus before the transplant were excluded) were eligible for this study. Participants were recruited consecutively from patients that underwent renal transplantation in Clinical Department of Nephrology and Dialysis of Regional Hospital, Szczecin, Poland or Department of Nephrology, Transplantation and Internal Medicine of Pomeranian Medical University, Szczecin, Poland from 2000 to 2007, and were subsequently medicated with tacrolimus as a part of immunosuppressive regimen. Patients who did not maintain graft function for at least 1 year after transplant were excluded. For the purpose of the study the patients were subdivided into two groups: patients with PTDM (n ¼ 56), and the controls, that is without PTDM (n ¼ 158). Characteristics of patients are given in Table 1 . Patients with hemoglobin A1c continuously over 6.5 mg per 100 ml, fasting plasma glucose over 126 mg per 100 ml or requiring insulin and/or oral hypoglycemic agents for more than 3 months at 1 year after transplantation were diagnosed as having PTDM. PTDM onset time in the studied group varied from 1 to 50 weeks (mean ± s.d: 6.8 ± 8.9 weeks).
The treatment protocol consisted of tacrolimus, mycophenolate mofetil and steroids, that is tacrolimus was initiated at 0.1 mg kg À1 per day with doses adjusted to keep trough levels between 10 and 12 ng ml À1 in the first month after transplantation and then between 8 and 10 ng ml
À1 . An initial oral dose of 2.0 g per day of mycophenolate mofetil was given to patients once a day, or was given in equally divided doses every 12 h. Methylprednisolone was given concomitantly: a dose of 500 mg on the day of surgery, Mann-Whitney U-test. *methylprednisolone was recalculated to prednisolone using r ¼ 1.25 cofactor tapered to 40 mg per day during the first week, 30 mg per day of prednisolone in the second week, 20 mg per day of prednisolone in the third week, 15 mg per day in the fourth week and 10 mg per day thereafter. Total corticosteroid dose for each patient during the first year of the study was calculated, methylprednisolone was recalculated to prednisolone using r ¼ 1.25 cofactor. All patients gave informed consent for this study, and the relevant ethics committee approved protocol of the study.
Genotyping
Genomic DNA was extracted from 450 ml of whole-blood samples using a nonorganic and nonenzymatic extraction method. Genotyping of each subject for the presence of CAPN10 gene variants (SNP-43: rs3792267:G4A, SNP-19: rs3842570 ins/del and SNP-63: rs5030952:C4T) was performed using PCR-based assays, previously described by Hoffstedt et al.
14 Briefly, DNA fragments containing polymorphic loci were amplified by means of PCR in three independent reactions, then SNP-19 alleles were distinguished by size after electrophoresis in ethidium-bromidestained agarose gel. Amplicons containing SNP-43 and SNP-63 were digested by NdeI or Hin6I endonuclease (Fermentas, Vilnius, Lithuania) and subsequently visualized after electrophoresis in agarose gel.
Statistical analysis
Categorical variables (that is, allele, genotype, haplotype frequencies, acute rejection episodes) were compared by the Fisher's exact test. The EH program (Jurg Ott, Rockefeller University, New York) was used to estimate haplotype frequencies and linkage disequilibria. Odds ratios (OR) and 95% confidence interval (95% CI) were calculated using the Newcombe-Wilson method without the continuity correction. Multivariate logistic regression model was used to test independent PTDM risk factors. Variables identified as potentially significant (Po0.1) were included in multivariate analysis. A P-value of less than 0.05 was considered statistically significant. All calculations were performed using Statistica 8.0 software package (StatSoft, Warsaw, Poland).
Results
Mean patient age, body mass index (BMI), acute rejection episode frequency and total steroid dose were higher in PTDM group compared to non-PTDM patients (controls). No differences in patients' sex, viral infection frequency nor donors' age between both groups were noted (Table 1) .
CAPN10 allele and haplotype frequencies in all posttransplant patients were similar to those obtained for healthy Polish population. 15 Allele and genotype frequencies for SNP-43 and SNP-19 were similar in both study groups. Contrary, frequency of SNP-63 minor allele was increased in PTDM patients, and that difference was nearly significant (P ¼ 0.056). Analysis of SNP-63 genotypes pointed to an association of SNP-63 heterozygosity and the risk of PTDM (OR ¼ 2.45, P ¼ 0.023). The CAPN10 genotype and allele frequencies in patients with and without PTDM are given in Table 2 .
The CAPN10 haplotype analysis revealed increased odds for PTDM development in patients carrying 1-1-2 haplotype (rs3792267:G-rs3842570:ins-rs5030952:T) compared to noncarriers. Moreover, 1-1-2 haplotype was significantly more frequent in PTDM patients. However, in the population studied, a group of 1-1-2 haplotype carriers was actually equal to SNP-63 T allele carriers. Individuals with 1-1-2/1-2-1 diplotype, a combination that was shown to be a risk factor for developing T2DM in general population, 8 were more frequent in PTDM group (12.5 vs 5.1%, OR ¼ 2.84), but this difference was not significant. The results of CAPN10 haplotype analysis are shown in Table 3 .
Variables identified as potentially significant-patient age, BMI, acute rejection episodes, total steroid dose and SNP-63 minor allele carrier status (that is, CT þ TT)-were included in further multivariate analysis. The results of logistic regression pointed to only two parameters as independent PTDM risk factors: BMI (OR ¼ 1.09 for each increase by 1 kg/m 2 ) and SNP-63 (OR ¼ 2.32 for minor T allele carriers, compared to CC wild-type homozygotes; Table 4 ).
Discussion
Kidney transplant recipients are particularly at risk to develop this complication as a consequence of immunosuppression. The incidence of new-onset diabetes mellitus is extremely variable among studies. A recent meta-analysis reported an incidence in the first year after transplantation varying from 2 to 50%. 16 This variable incidence of PTDM is probably related to differences in population demographics or a variety of diagnostic criteria between studies. In the present study the incidence of PDTM observed among patients of Polish ethnicity falls within the range of the above-cited meta-analysis.
In the present study we observed an association between several parameters and PTDM, that is, mean patient age, BMI, acute rejection episode frequency and total steroid dose were higher in PTDM group compared to non-PTDM patients. Those parameters, as well as hepatitis C virus infection, and family history of diabetes, are known risk factors for PTDM in the renal transplant population. 17 We did not observe any significant differences in the frequency of viral infections between PDTM patients and the controls. Family history of DM was not included in the analysis, because complete data was not available, and thus can be pointed out as one of the limitations of the current study.
The type of immunosuppression had the strongest impact on the incidence of PTDM. Both cyclosporin A and tacrolimus are associated with increased PTDM risk. Most of the studies have reported a greater risk for tacrolimus than cyclosporin A. 18, 19 However, corticosteroids, with their dose-dependent effect to stimulate insulin resistance, are associated with the highest risk of PTDM. 19, 20 The drug regimen administered to both study groups was comparable, including steroid administration, therefore it seems that medication factor did not influenced the study results. The present study revealed a significant association between PTDM and CAPN10 gene SNP-63 (rs5030952:C4T) polymorphism, as well as 1-1-2 haplotype (derived from SNP-43 (rs3792267), SNP-19 (rs3842570) and SNP-63 (rs5030952)). The potential role of SNP-63 as an independent factor of PTDM risk was confirmed in multivariate analysis. All three polymorphism studied are located in noncoding intronic sequences of CAPN10 gene. However, they may affect either CAPN10 gene expression or mRNA stability. 8, 10, 11 Some studies had also postulated that higher levels of tacrolimus were associated to an increased risk of PTDM. 21 However, this is not the case in the present study as due to therapeutic monitoring of blood levels of the drug, tacrolimus blood concentrations were similar in both evaluated groups. The results of several prospective studies performed up to date suggest that tacrolimus affects insulin release, probably inhibiting its production, but does not precipitate insulin resistance. 17 CAPN10 is a protease that may contribute to the development of diabetes, similarly to prohormone-processing carboxypeptidase E and prohormone convertase-1, both of which are associated with diabetes and obesity. 8 It was revealed that variation within CAPN10 gene might increase plasma glucose levels and significantly decrease insulin secretory response. 22 Hence, we speculate that SNP-63 within CAPN10 gene, potentially influencing clapain-10 expression, may be involved as PTDM risk factor in patients treated with tacrolimus, which inhibits insulin production.
The results of genetic studies of T2DM susceptibility and CAPN10 gene polymorphism in general population are not conclusive, because only some of studies confirm an existence of such association. Large meta-analyses point mainly to SNP-43 and SNP-44 (rs2975760) as moderate risk factors for T2DM. 12, 13 However, SNP-63 minor allele frequency is the lowest of three SNP studied, and it is suggested that rare polymorphisms are generally suspected to have more potent impact as disease risk factors, compared to more common variants. 23 Moreover, it was postulated that ethnic differences may influence the association between CAPN10 and T2DM. 24 Although individuals with 1-1-2/1-2-1 diplotype were more frequent in PTDM group, we were unable to confirm an association between PTDM and that 'high T2DM risk diplotype', as evaluated in an European 25 possibly due to lower number of cases. However, postulated PTDM induction mechanism differs from that for T2DM, and includes additional risk factors, for example, the immunosuppressive regimen, 17 which may be also responsible for observed discrepancies. Till date, noncoding sequence variation has been associated with some common diseases with complex inheritance. Assaying the functional consequence of such variation is difficult, although novel comparative genomic approaches can enhance our ability to identify functional elements in coding and noncoding sequence as well as improve the ability to assay functional consequence by highlighting control regions unlikely to be functional. 26 This is the first study of CAPN10 polymorphism in relation to PTDM risk, so the results should be treated as a preliminary finding, as a false-positive association cannot be totally excluded. If our observation is confirmed, replacing tacrolimus with other immunosuppressant could be warranted in patients at high risk of PTDM diagnosed by CAPN10 genotyping. Finally, the application of SNP-63 (rs5030952:C4T) as a marker of PTDM should be verified by further independent studies. 8 commonly used in literature (allele 1: rs3792267G, rs3842570 del, rs5030952C; allele 2: rs3792267A, rs3842570 ins and rs5030952T); Fisher's exact test, calculated in relation to haplotype 1-2-1 and diplotype 1-2-1/1-2-1 frequency as referent, except * to noncarriers.
